1
|
Mazzola G, Bergamaschi L, Pedone C, Vincini M, Pepa M, Zaffaroni M, Volpe S, Rombi B, Doyen J, Fossati P, Haustermans K, Høyer M, Langendijk J, Matute R, Orlandi E, Rylander H, Troost E, Orecchia R, Alterio D, Jereczek-Fossa B. Patients' needs in proton therapy: A survey among ten European facilities. Clin Transl Radiat Oncol 2023; 43:100670. [PMID: 37736140 PMCID: PMC10509656 DOI: 10.1016/j.ctro.2023.100670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Revised: 07/30/2023] [Accepted: 08/19/2023] [Indexed: 09/23/2023] Open
Abstract
Aims The number of Proton Therapy (PT) facilities is still limited worldwide, and the access to treatment could be characterized by patients' logistic and economic challenges. Aim of the present survey is to assess the support provided to patients undergoing PT across Europe. Methods Through a personnel contact, an online questionnaire (62 multiple-choice and open-ended questions) via Microsoft Forms was administered to 10 European PT centers. The questionnaire consisted of 62 questions divided into 6 sections: i) personal data; ii) general information on clinical activity; iii) fractionation, concurrent systemic treatments and technical aspects of PT facility; iv) indication to PT and reimbursement policies; v) economic and/ or logistic support to patients vi) participants agreement on statements related to the possible limitation of access to PT. A qualitative analysis was performed and reported. Results From March to May 2022 all ten involved centers filled the survey. Nine centers treat from 100 to 500 patients per year. Paediatric patients accounted for 10-30%, 30-50% and 50-70% of the entire cohort for 7, 2 and 1 center, respectively. The most frequent tumours treated in adult population were brain tumours, sarcomas and head and neck carcinomas; in all centers, the mean duration of PT is longer than 3 weeks. In 80% of cases, the treatment reimbursement for PT is supplied by the respective country's Health National System (HNS). HNS also provides economic support to patients in 70% of centers, while logistic and meal support is provided in 20% and 40% of centers, respectively. PT facilities offer economic and/or logistic support in 90% of the cases. Logistic support for parents of pediatric patients is provided by HNS only in one-third of centers. Overall, 70% of respondents agree that geographic challenges could limit a patient's access to proton facilities and 60% believe that additional support should be given to patients referred for PT care. Conclusions Relevant differences exist among European countries in supporting patients referred to PT in their logistic and economic challenges. Further efforts should be made by HNSs and PT facilities to reduce the risk of inequities in access to cancer care with protons.
Collapse
Affiliation(s)
- G.C. Mazzola
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - L. Bergamaschi
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - C. Pedone
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - M.G. Vincini
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - M. Pepa
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - M. Zaffaroni
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - S. Volpe
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - B. Rombi
- Proton Therapy Center, Trento, Italy
| | - J. Doyen
- Centre Antoine Lacassagne, Nice, France
| | - P. Fossati
- MedAustron Ion Therapy Center, Wiener Neustadt, Austria
| | | | - M. Høyer
- Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
| | - J.A. Langendijk
- University Medical Center Groningen, Groningen, The Netherlands
| | - R. Matute
- Centro de Protonterapia Quironsalud, Madrid, Spain
| | - E. Orlandi
- CNAO National Center for Oncological Hadrontherapy, Pavia, Italy
| | | | - E.G.C. Troost
- Faculty of Medicine and University Hospital Carl Gustav Carus, Department of Radiotherapy and Radiation Oncology, Dresden, Germany
- OncoRay - National Center for Radiation Research in Oncology: Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
- Institute of Radiooncology - OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - R. Orecchia
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - D. Alterio
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - B.A. Jereczek-Fossa
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| |
Collapse
|
2
|
Pereira S, Deneuve S, Iacovelli NA, Duclos M, Cavallo A, Nokovitch L, Roux PE, Girodet D, Poupart M, Zrounba P, Claude L, Ferella L, Valdagni R, Foray N, Orlandi E, Rancati T. Predicting Acute Radio-Induced Toxicity for Head and Neck Cancer Patients: Combining Dosimetry with Biomarker Data, Disclosing a Synergistic Effect. Int J Radiat Oncol Biol Phys 2023; 117:e615. [PMID: 37785847 DOI: 10.1016/j.ijrobp.2023.06.1993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) We aimed to establish the added value of combining dosimetry with a binary blood assay for radiosensitivity based on quantification of pATM protein (RADIODTECT©) to predict acute radiotherapy (RT) induced mucositis (MUC) and dysphagia (DYS) in head & neck cancer patients (pts). MATERIALS/METHODS We enrolled 101 pts prospectively scored for acute toxicity with CTCAE. We considered four endpoints: grade≥2 (G2+) and grade≥3 (G3+) MUC, G2+, and G3+ DYS. We dichotomized the pATM concentration to define radiosensitive (RS) vs. radioresistant (RR) pts using previously described cutoffs for G2+ (57.8 ng/mL) and G3+ toxicity (46 ng/mL). We did RADIODTECT© and toxicity scoring blindly. We considered two already published NTCP models, including (i) the Equivalent Uniform Dose to the oral cavity (n = 0.05, EUD_OC, Odds Ratio [OR] = 1.02) and the mean dose to the parotid glands (Dmean_PG, OR = 1.06) for MUC and (ii) EUD_OC (OR = 1.04), the glottic larynx EUD (n = 0.35, EUD_GL, OR = 1.02) and the volume of pharyngeal constrictor muscles receiving>50Gy (V50Gy_CM, OR = 1.02) for DYS. To account for the association of toxicity with the dose distribution in multiple organs at risk (OARs), we derived a "Weighted Dose Score" (WDS) as a linear combination of the dose factors, using their β-coefficients (= lnOR) as weights. WDS for MUC (WDS_OM) = 0.06*Dmean_PG + 0.02*EUD_OC WDS for DYS (WDS_DYS) = 0.02*V50Gy_CM + 0.02*EUD_GL + 0.04*EUD_OC We used WDS as a comprehensive dose feature to fit a dose response and allowed WDS50 (i.e., the WDS associated with 50% toxicity probability) to be different for RR (WDS50_RR) and RS pts (WDS50_RS). The dose-modifying factor (DMF) is the ratio of WDS50_RS/WDS50_RR. It measures the horizontal shift of the dose-response curve when comparing RS vs. RR pts. RESULTS We scored G2+ and G3+ MUC in 80 and 41 pts; G2+ and G3+ DYS in 73 and 35 pts. The average concentration of pATM was 57.4ng/mL (sd 22.3ng/mL): 53/101 pts were classified as RS for G2+ toxicity and 35/101 as RS for G3+. On the whole cohort, the RADIODTECT© did not significantly associate with the risk of toxicity. However, we found two different dose-response curves at low WDS. There, the intrinsic biological sensitivity significantly affects the toxicity probability: ORs for RADIODTECT© are 2.6/2.4 for G2+/G3+ DYS, 6.4/2.9 for G2+/G3+ MUC. Furthermore, the difference in the incidence of side effects in RR vs. RS pts decreases as the WDS increases, reaching a region where the doses of OARs play a significant role. When combined with WDS, the RADIODTECT© effectively predicted RS pts, with DMF ranging from 0.77 for G3+ DYS to 0.40 for G2+ MUC. CONCLUSION These findings support the hypothesis that dose and biomarkers act synergistically; biologically based radiosensitivity plays a significant role when OARs are exposed at lower doses, while high doses of OARs determine toxicity irrespective of the underlying single pt biological characterization.
Collapse
Affiliation(s)
- S Pereira
- Neolys Diagnostics, LYON CEDEX 08, France
| | | | - N A Iacovelli
- Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Radiation Oncology, Milan, Italy
| | - M Duclos
- Neolys Diagnostics, Entzheim, France
| | - A Cavallo
- Fondazione IRCCS Istituto Nazionale dei Tumori, Division of Medical Physics, Milan, Italy
| | | | - P E Roux
- Centre Léon Bérard, LYON, France
| | | | - M Poupart
- Centre Léon Bérard, Radiation Oncology Department, Lyon, France
| | | | - L Claude
- Centre Léon Bérard, Radiation Oncology Department, Lyon, France
| | | | | | | | - E Orlandi
- National Center for Oncological Hadrontherapy (CNAO), Radiation Oncology Clinical Department, Pavia, Italy
| | - T Rancati
- Fondazione IRCCS Istituto Nazionale dei Tumori, Data Science Unit, Milan, Italy
| |
Collapse
|
3
|
Barcellini A, Vitolo V, Cobianchi L, Vanoli A, Butturini G, Brugnatelli S, Pagani A, Fossati P, Preda L, Peloso A, Klersy C, Facoetti A, Molinelli S, Ciocca M, Imparato S, Pecorilla M, Orlandi E, Valvo F. Preoperative Carbon Ion Radiotherapy (CIRT) with Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma (PCa): A Multicenter Prospective Phase II Clinical Study (Pioppo Study NCT 03822936). Int J Radiat Oncol Biol Phys 2023; 117:e347-e348. [PMID: 37785206 DOI: 10.1016/j.ijrobp.2023.06.2417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Preoperative chemoradiation and surgery may improve survival for resectable (Re) or borderline resectable (BRe) PCa. However, there is a lack of evidence regarding the feasibility of combined chemotherapy (CT) and CIRT in the neoadjuvant setting for Re/BRe PCa, especially in the Caucasian population. To assess the safety and efficacy of this challenging combination, we designed a prospective multicentric single-arm phase II trial MATERIALS/METHODS: PIOPPO trial was opened in September 2014. We prospectively treated patients with Re/BRe Pca with a neoadjuvant CT (3 cycles of FOLFIRINOX) and a short-course of CIRT (38.4 GyRBE, 8 fractions, 4 fractions per week) planned with 4D-imaging and delivered with breath-gating and rescanning. Four-6 weeks after CIRT patients (pts) received surgery followed by adjuvant-CT (FOLFIRINOX for 9 or gemcitabine for 6 cycles). After each step patients underwent a re-staging. The primary endpoint was Local Progression Free Survival (LPFS). RESULTS Fourteen (47%) of the foreseen 30 pts were evaluated for enrollment. There were 4 screening failures for duodenum infiltration. Ten Caucasian pts (M = 7; 70%; F = 3;30%) with a median age of 65.5 (range:46-76) started the treatment. There were four (40%) Re and 6 (60%) BRe Pca. 100% of the Re and 50% of BRe PCa completed the planned combined treatment for a total of 7 (70%) pts. Three (30%) pts developed systemic progression after CT and underwent palliative care (2 cases) or a second line of CT (1 case). With regards to toxicities, we recorded 2 (28.6%) cases of neutropenia during CT, none acute CIRT toxicity and one (14%) case of intra-operative ulceration of the gastro-enteric anastomosis. Moreover, we reported one (14%) case of fatal liver failure due to portal vein stenosis due to the combo approach (CT+CIRT+surgery). Six (86%) pts experienced Tumor Regression Grade (TRG) = 2 according to the College of American Pathologists (CAP) and 1 (14%) a TRG = 3. At the last follow-up, among pts who completed the scheme, 2 (28%) are currently alive and disease-free at 57 and 49 months, respectively. With a median follow-up of 13 months, the median LPFS was 9.4 months (range:4.9-57), with 1 case (14%) of systemic progression and 3 cases (43%) of local recurrence + systemic progression. The study was early closed due to low accrual in August 2022. CONCLUSION Although the small sample size limits the interpretation of the endpoints, a neoadjuvant approach combining CT and a short course of CIRT for resectable/borderline Pca seems feasible. Liver toxicity was similar to the Japanese series and needs to deepen investigation on the vascular dose constraints and surgical techniques. Considering the worse outcomes, a better selection of patients to treat also with a centralized imaging interpretation is mandatory.
Collapse
Affiliation(s)
- A Barcellini
- National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy
| | - V Vitolo
- National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - L Cobianchi
- General Surgery Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
| | - A Vanoli
- Anatomic Pathology Unit, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - G Butturini
- Hepato Bilio Pancreatic Surgery Department "P. Pederzoli" Hospital, Peschiera del Garda, VR, Italy
| | - S Brugnatelli
- Medical Oncology Department, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - A Pagani
- Medical Oncology Department, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - P Fossati
- MedAustron Ion Therapy Center, Wiener Neustadt, Austria
| | - L Preda
- Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Radiology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - A Peloso
- Department of Visceral and Transplantation Surgery, University of Geneva Hospitals, Geneva, GE, Switzerland
| | - C Klersy
- Clinical Epidemiology & Biometry Unit, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
| | - A Facoetti
- National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - S Molinelli
- National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - M Ciocca
- National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - S Imparato
- National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - M Pecorilla
- National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - E Orlandi
- National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - F Valvo
- National Centre of Oncological Hadrontherapy, Pavia, Italy
| |
Collapse
|
4
|
Loap P, Barcellini A, de Marzi L, Orlandi E, Kirova Y. Neutron brachytherapy in the modern era: Indications and evidence. Cancer Radiother 2023; 27:170-177. [PMID: 36759242 DOI: 10.1016/j.canrad.2022.08.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Revised: 07/01/2022] [Accepted: 08/26/2022] [Indexed: 02/09/2023]
Abstract
Hadrontherapy is a form of radiation therapy (RT) that relies on heavy particles, such as proton, heavy ions, or neutrons, to enhance anti-tumoral efficacy based on their specific dosimetric and radio-biological properties. Neutrons are characterized by specific radiobiological properties that might deserve greater consideration, including the high linear energy transfer and the low oxygen enhancement ratio. Neutron brachytherapy, relying on interstitial or intracavitary neutron sources, has been developed since the 1950s using Californium-252 (252Cf) as a mixed emitter of fission fast neutrons and γ-photos. However, the place of NBT in the era of modern radiation therapy is yet to be precisely defined. In this systematic review, we aim to provide an up-to-date analysis of current experience and clinical evidence of NBT in the XXI th century, by answering the following clinical questions: How is NBT currently delivered? What are the current efficacy data and tolerance profiles of NBT?
Collapse
Affiliation(s)
- P Loap
- Department of Radiation Oncology, Institut Curie, Paris, France.
| | - A Barcellini
- Radiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy; Radiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - L de Marzi
- Department of Radiation Oncology, Institut Curie, Paris, France
| | - E Orlandi
- Radiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - Y Kirova
- Department of Radiation Oncology, Institut Curie, Paris, France
| |
Collapse
|
5
|
Luciano M, Sampogna G, Del Vecchio V, Giallonardo V, Di Cerbo A, Palummo C, Malangone C, Lampis D, Veltro F, Bardicchia F, Ciampini G, Orlandi E, Moroni A, Biondi S, Piselli M, Menculini G, Nicolò G, Pompili E, Carrà G, Fiorillo A. Medium and long-term efficacy of psychoeducational family intervention for bipolar I disorder: Results from a real-world, multicentric study. Bipolar Disord 2022; 24:647-657. [PMID: 35114727 PMCID: PMC9790519 DOI: 10.1111/bdi.13182] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
OBJECTIVES This study aims to explore the long-term efficacy of a psychoeducational family intervention (PFI) in bipolar I disorder at one and five years post-intervention in terms of improvement of: (1) patients' symptoms and global functioning and (2) relatives' objective and subjective burden and coping strategies. METHODS This is a multicentre, real-world, controlled, outpatient trial. Recruited patients and key-relatives were consecutively allocated to the experimental intervention or treatment as usual. Patients were assessed at baseline, and after one and five years. RESULTS One hundred and thirty-seventh number families have been recruited; 70 have been allocated to the experimental intervention, and 67 have been allocated to the control group. We observed an increasing positive effect of the PFI on patients' clinical status, global functioning and objective and subjective burden after one year. We also found a reduction in the levels of relatives' objective and subjective burden and a significant improvement in the levels of perceived professional support and of coping strategies. The efficacy of PFI on patients' clinical status was maintained at five years from the end of the intervention, in terms of relapses, hospitalizations and suicide attempts. CONCLUSIONS The study showed that the provision of PFI in real-world settings is associated with a significant improvement of patients' and relatives' mental health and psychosocial functioning in the long term. We found that the clinical efficacy of the intervention, in terms of reduction of patients' relapses, hospitalization and suicide attempts, persists after 5 years. It is advisable that PFI is provided to patients with BD I in routine practice.
Collapse
Affiliation(s)
- Mario Luciano
- Department of PsychiatryUniversity of Campania “Luigi Vanvitelli”NaplesItaly
| | - Gaia Sampogna
- Department of PsychiatryUniversity of Campania “Luigi Vanvitelli”NaplesItaly
| | - Valeria Del Vecchio
- Department of PsychiatryUniversity of Campania “Luigi Vanvitelli”NaplesItaly
| | | | - Arcangelo Di Cerbo
- Department of PsychiatryUniversity of Campania “Luigi Vanvitelli”NaplesItaly
| | - Carmela Palummo
- Department of PsychiatryUniversity of Campania “Luigi Vanvitelli”NaplesItaly
| | | | | | - Franco Veltro
- Mental Health Department of CampobassoCampobassoItaly
| | | | | | | | | | | | | | | | | | | | - Giuseppe Carrà
- Department of Medicine and SurgeryUniversity of Milano BicoccaMonzaItaly
| | - Andrea Fiorillo
- Department of PsychiatryUniversity of Campania “Luigi Vanvitelli”NaplesItaly
| |
Collapse
|
6
|
Cuffini E, Casale C, Mantovani C, Gastino A, Lo Zito B, Blasi L, Bongiovanni D, Orlandi E, Cerrato M, Vella A, Leardi S, Chiofalo V, Cavallin C, Iorio G, Ricardi U, Levis M. OC-0925 Early adjuvant RT as a predictor of improved outcomes in patients with grade II and III meningiomas. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02705-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Loap P, Mirandola A, De Marzi L, Barcellini A, Vitolo V, Iannalfi A, Dendale R, Kirova Y, Orlandi E. PD-0172 Multi-parameter patient selection strategy for Hodgkin lymphoma proton therapy. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02777-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Loap P, Mirandola A, De Marzi L, Barcellini A, Vitolo V, Iannalfi A, Dendale R, Orlandi E, Kirova Y. PD-0175 Cardiac conduction system exposure during modern radiation therapy for mediastinal Hodgkin lymphoma. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02780-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Ronchi S, Vischioni B, Cicchetti A, Bonora M, Ingargiola R, Rossi E, Russo S, Ciocca M, Orlandi E. MO-0482 Carbon ion radiotherapy for head and neck mucosal melanoma: single-center experience in 40 patients. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02376-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Fiore M, Ghirelli A, Molinelli S, Magro G, Chalaszczyk A, Mairani A, Donatelli A, Imparato S, Ciocca M, Orlandi E. MO-0150 Sacral insufficiency fractures after CIRT for sacral chordoma: dosimetric and LET analysis. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02310-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
11
|
Chalaszczyk A, Fiore M, Barcellini A, Vitolo V, Ghirelli A, Russo S, Molinelli S, Vai A, Orlandi E. MO-0149 Preliminary results of carbon ion radiotherapy for malignant peripheral nerve sheath tumors. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02309-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Riva G, Fiorina E, Cavallo I, Molinelli S, Vai A, Ciocca M, Iannalfi A, Orlandi E. OC-0090 Temporal lobe necrosis after proton therapy for skull base tumors and NTCP models evaluation. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02466-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
13
|
Cerrato M, Badellino S, Menegatti F, Bonavero I, Grossi C, Lo Zito B, Orlandi E, Gastino A, Cuffini E, Blasi L, Mantovani C, Parise R, Ricardi U, Levis M. PD-0672 Cardiac toxicity predicts mortality in NSCLC patients: interim analysis of the LUNG-HEART Study. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02919-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
Gioscio E, Rancati T, De Cecco L, Barbara A, Noris Chiorda B, Badenchini F, Giandini T, Cicchetti A, Zaffaroni N, Doldi V, Mancinelli E, Serafini M, Devecchi A, Andreoli L, Orlandi E, Valdagni R. PD-0161 Single-patient microbiota & inflammation profiles modulate dose-response curves for acute toxicity. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02766-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
molinelli S, Vai A, Russo S, Loap P, Meschini G, Magro G, Paganelli C, Barcellini A, Vitolo V, Ciocca M, Orlandi E. MO-0635 The need for treatment adaptation in carbon ion radiotherapy of pancreatic cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02393-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Iacovelli N, Rancati T, Ingargiola R, Alfieri S, De Cecco L, Badenchini F, Cavallo A, Cicchetti A, Zaffaroni N, Doldi V, Mancinelli E, Serafini M, Devecchi A, Valdagni R, Orlandi E. MO-0381 Saliva microbiota and inflammation markers predict acute toxicity after RT for head-and-neck cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02347-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
17
|
Vai A, Molinelli S, Rossi E, Iacovelli N, Magro G, Cavallo A, Pignoli E, Rancati T, Mirandola A, Ingargiola R, Vischioni B, Bonora M, Ronchi S, Ciocca M, Orlandi E. PO-1509 Proton therapy for nasopharyngeal cancer: dosimetric and NTCP analysis supporting clinical decision. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03473-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Anemoni L, Mascayano I, Preda L, Orlandi E, Cadeo M, Mancin A, Piazzolla M, Tampellini S. PO-1855 application of advanced mri techniques in patients affected by meningioma treated with protontherapy. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03818-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Barcellini A, Mirandola A, Fiore M, Orlandi E, Cobianchi L. Omentum flap as a spacer before carbon ion radiotherapy for gynecological recurrences. A technical note. Cancer Radiother 2022; 26:599-603. [DOI: 10.1016/j.canrad.2021.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 12/20/2021] [Accepted: 12/22/2021] [Indexed: 10/18/2022]
|
20
|
Barcellini A, Dal Mas F, Paoloni P, Loap P, Cobianchi L, Locati L, Rodríguez-Luna MR, Orlandi E. Please mind the gap-about equity and access to care in oncology. ESMO Open 2021; 6:100335. [PMID: 34902710 PMCID: PMC8671867 DOI: 10.1016/j.esmoop.2021.100335] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 10/26/2021] [Accepted: 11/11/2021] [Indexed: 12/25/2022] Open
Affiliation(s)
- A Barcellini
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - F Dal Mas
- Department of Management, Lincoln International Business School, University of Lincoln, Lincoln, UK; Ipazia Observatory on Gender Research, Rome, Italy; Interdepartmental Research Center "Organization and Governance of the Public Administration", University of Pavia, Pavia, Italy
| | - P Paoloni
- Ipazia Observatory on Gender Research, Rome, Italy; Department of Law and Economics of Productive Activities, Sapienza University of Rome, Rome, Italy
| | - P Loap
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy; Department of Radiation Oncology, Institut Curie, Paris, France
| | - L Cobianchi
- Department of General Surgery, IRCCS Policlinico San Matteo Foundation, Pavia, Italy; Department of Clinical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
| | - L Locati
- Unit of Translational Oncology, IRCCS ICS Maugeri, University of Pavia, Pavia, Italy
| | - M R Rodríguez-Luna
- Institute for Research against Digestive Cancer (IRCAD), Strasbourg, France
| | - E Orlandi
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
| |
Collapse
|
21
|
Morelli L, Buizza G, Palombo M, Riva G, Fontana G, Imparato S, Iannalfi A, Orlandi E, Paganelli C, Baroni G. Analysis of tumour microstructure estimation from conventional diffusion MRI and application to skull-base chordoma . Annu Int Conf IEEE Eng Med Biol Soc 2021; 2021:3761-3764. [PMID: 34892054 DOI: 10.1109/embc46164.2021.9630129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Skull-base chordoma (SBC) is a rare tumour whose molecular and radiological characteristics are still being investigated. In neuro-oncology microstructural imaging techniques, like diffusion-weighted MRI (DW-MRI), have been widely investigated, with the apparent diffusion coefficient (ADC) being one of the most used DW-MRI parameters due to its ease of acquisition and computation. ADC is a potential biomarker without a clear link to microstructure. The aim of this work was to derive microstructural information from conventional ADC, showing its potential for the characterisation of skull-base chordomas. Sixteen patients affected by SBC, who underwent conventional DW-MRI were retrospectively selected. From mono-exponential fits of DW-MRI, ADC maps were estimated using different sets of b-values. DW-MRI signals were simulated from synthetic substrates , which mimic the cellular packing of a tumour tissue with well-defined microstructural features. Starting from a published method, an error-driven procedure was evaluated to improve the estimates of microstructural parameters obtained through the simulated signals. A quantitative description of the tumour microstructure was then obtained from the DW-MRI images. This allowed successfully differentiating patients according to histologically-verified cell proliferation information.Clinical Relevance - The impact on cancer management derives from the expected improvement of radiation treatment quality tailored to a patient-specific non-invasive description of tumour microstructure.
Collapse
|
22
|
Dusi V, Barcellini A, Greco A, Vitolo V, Vai A, Mirandola A, Zambrino D, Roccio M, Coccia M, Turco A, Sanzo A, Vicentini A, Ghio S, Orlandi E, Rordorf R. Hadrontherapy for intra- or para-cardiac tumors: evaluation of cardiac radiation dose distribution and acute cardiac effects. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
There is growing interest in the possibility of using X-rays and hadrons (protons and carbon ions) for antiarrhythmic purposes both at the ventricular and the atrial level, but knowledge about the effects on cardiac tissue outside the target is still limited. Hadron therapy has the dosimetric advantage over photons of a greater ability to concentrate high doses on the target while minimizing the off-target dose. Oncological studies have shown a linear relationship between the mean total heart dose (Dm-heart) of X-rays and the long-term risk of heart damage, particularly when the Dm-heart is>5 Gray (Gy).
Objectives
We designed a prospective study aimed at investigating the effect of heavy particles on cardiac structure and function and on cardiac rhythm in patients undergoing hadrontherapy for intra or para-cardiac tumors.
Methods
Patients candidates to hadrontherapy with a mean predicted cardiac dose grather than zero underwent close cardiological monitoring including blood pressure detection, 12-lead ECG, 12-lead Holter ECG (including time-domain indices of heart rate variability in all cases and Brugada leads in selected cases), cardiac US and cardiac (troponin and natriuretic peptides) and inflammatory biomarkers. These assessments were obtained at baseline, during (ECG and biomarkers only) and at the end of the hadrontherapy cycle, and then every 3–6 months as appropriate. Physicists and radiotherapists collaborated to implement a robust optimization of the treatment plan aimed at minimizing cardiac dose. We present the results of the monitoring up to the end of the hadrontherapy.
Results
17 consecutive patients (56±18 years, range 20–77 years, 59% male) have been enrolled to date, including 3 cases (18%) of intra-cardiac tumors (2 primary and 1 metastatic), who have undergone to 16±6 sessions of radiotherapy each, in 71% of cases with respiratory gating during delivery. Most patients (76%) were treated with carbon ions, the remaining with protons (mean total dose on the neoplastic target 51.8±10.7 Gy, from 2 to 4.2 Gy per fraction). Sixty-one percent of patients had ≥1 cardiovascular risk factor, 6% had a known heart disease (valvular cardiomyopathy despite aortic valve replacement with biological prosthesis and post-surgical pericarditis). The mean dose on the whole heart was 3.58±2.05 Gy, the maximum dose was 33.78±23.99 Gy, with a very variable dose distribution on cardiac substructures depending on the tumor site (table). At the end of the scheduled radiotherapy sessions (24±9 days), no significant changes were observed in cardiac function, cardiac rhythm, ventricular repolarization, biomarkers and autonomic indices.
Conclusions
Hadrontherapy with protons and carbon ions aimed at the treatment of para-cardiac or intra-cardiac tumors allowed to maintain a low heart Dm and showed no signs of acute cardiac toxicity. The collection of potential cardiac effects in the medium and long term is ongoing.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- V Dusi
- Policlinic Foundation San Matteo IRCCS, Cardiac Intensive Care Unit, Arrhythmia and Electrophysiology and Experimental Cardiology, Pavia, Italy
| | - A Barcellini
- National Centre for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - A Greco
- Policlinic Foundation San Matteo IRCCS, Division of Cardiology, Pavia, Italy
| | - V Vitolo
- National Centre for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - A Vai
- National Centre for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - A Mirandola
- National Centre for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - D Zambrino
- National Centre for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - M Roccio
- Policlinic Foundation San Matteo IRCCS, Department of Gynecology, Pavia, Italy
| | - M Coccia
- University of Pavia, Department of Molecular Medicine, Pavia, Italy
| | - A Turco
- Policlinic Foundation San Matteo IRCCS, Division of Cardiology, Pavia, Italy
| | - A Sanzo
- Policlinic Foundation San Matteo IRCCS, Cardiac Intensive Care Unit, Arrhythmia and Electrophysiology and Experimental Cardiology, Pavia, Italy
| | - A Vicentini
- Policlinic Foundation San Matteo IRCCS, Cardiac Intensive Care Unit, Arrhythmia and Electrophysiology and Experimental Cardiology, Pavia, Italy
| | - S Ghio
- Policlinic Foundation San Matteo IRCCS, Division of Cardiology, Pavia, Italy
| | - E Orlandi
- National Centre for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - R Rordorf
- Policlinic Foundation San Matteo IRCCS, Cardiac Intensive Care Unit, Arrhythmia and Electrophysiology and Experimental Cardiology, Pavia, Italy
| |
Collapse
|
23
|
Ricotti R, Pella A, Mirandola A, Fiore MR, Chalaszczyk A, Paganelli C, Antonioli L, Vai A, Tagaste B, Belotti G, Rossi M, Ciocca M, Orlandi E, Baroni G. Dosimetric effect of variable rectum and sigmoid colon filling during carbon ion radiotherapy to sacral chordoma. Phys Med 2021; 90:123-133. [PMID: 34628271 DOI: 10.1016/j.ejmp.2021.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 08/13/2021] [Accepted: 09/23/2021] [Indexed: 11/17/2022] Open
Abstract
PURPOSE Carbon ion radiotherapy (CIRT) is sensitive to anatomical density variations. We examined the dosimetric effect of variable intestinal filling condition during CIRT to ten sacral chordoma patients. METHODS For each patient, eight virtual computed tomography scans (vCTs) were generated by varying the density distribution within the rectum and the sigmoid in the planning computed tomography (pCT) with a density override approach mimicking a heterogeneous combination of gas and feces. Totally full and empty intestinal preparations were modelled. In addition, five different intestinal filling conditions were modelled by a mixed density pattern derived from two combined and weighted Gaussian distributions simulating gas and feces respectively. Finally, a patient-specific mixing proportion was estimated by evaluating the daily amount of gas detected in the cone beam computed tomography (CBCT). Dose distribution was recalculated on each vCT and dose volume histograms (DVHs) were examined. RESULTS No target coverage degradation was observed at different vCTs. Rectum and sigma dose degradation ranged respectively between: [-6.7; 21.6]GyE and [-0.7; 15.4]GyE for D50%; [-377.4; 1197.9] and [-95.2; 1027.5] for AUC; [-1.2; 10.7]GyE and [-2.6; 21.5]GyE for D1%. CONCLUSIONS Variation of intestinal density can greatly influence the penetration depth of charged particle and might compromise dose distribution. In particular cases, with large clinical target volume in very close proximity to rectum and sigmoid colon, it is appropriate to evaluate the amount of gas present in the daily CBCT images even if it is totally included in the reference planning structures.
Collapse
Affiliation(s)
- R Ricotti
- Bioengineering Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
| | - A Pella
- Bioengineering Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - A Mirandola
- Medical Physics Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - M R Fiore
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - A Chalaszczyk
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - C Paganelli
- Department of Electronics Information and Bioengineering, Politecnico di Milano, Milano, Italy
| | - L Antonioli
- Bioengineering Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - A Vai
- Medical Physics Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - B Tagaste
- Bioengineering Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - G Belotti
- Department of Electronics Information and Bioengineering, Politecnico di Milano, Milano, Italy
| | - M Rossi
- Department of Electronics Information and Bioengineering, Politecnico di Milano, Milano, Italy
| | - M Ciocca
- Medical Physics Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - E Orlandi
- Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - G Baroni
- Bioengineering Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy; Department of Electronics Information and Bioengineering, Politecnico di Milano, Milano, Italy
| |
Collapse
|
24
|
Alfieri S, Marceglia S, Filippini D, Bergamini C, Resteghini C, Cavalieri S, Peris K, Sollena P, Piccerillo A, Gualdi G, Ascierto P, Curvietto M, Palla M, De Giorgi V, Eibenschutz L, Spagnolo F, Orlandi E, Locati L, Licitra L, Bossi P. 1065P A retrospective multicenter Italian analysis of the effect of longer vismodegib intake in 68 basal cell carcinoma patients who achieved clinical complete remission. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
25
|
Buizza G, Zampini M, Sablone G, Fontana G, Imparato S, Riva G, Iannalfi A, Orlandi E, Paganelli C, Baroni G. PH-0212 Optimization of intravoxel incoherent motion diffusion MRI for brain tumours biomarkers estimation. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07264-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
26
|
Rancati T, Deneuve S, Bastogne T, Duclos M, Bois P, Bachmann P, Nokovitch L, Roux P, Girodet D, Puopart M, Zrounba P, Claude L, Ferella L, Orlandi E, Foray N, Perreira S. PD-0784 Predicting toxicity after RT for head and neck cancer: combining dosimetry with a biomarker. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07063-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
27
|
Anemoni L, Mancin A, Preda L, Cadeo M, Mascayano I, Tampellini S, Orlandi E. PO-1948 comparison between the use of PET-CT and high-field MRI 3.0T in adenoid cystic carcinoma. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08399-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
28
|
Meschini G, Calabrese D, De Mori Bajolin F, Vai A, Fontana G, Molinelli S, Pella A, Imparato S, Vitolo V, Barcellini A, Orlandi E, Paganelli C, Baroni G. PO-1660 Investigating the generation of synthetic CT for abdominal tumors treated with particle therapy. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08111-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
29
|
Tambas M, van der Laan H, Steenbakkers R, Doyen J, Timmermann B, Orlandi E, Hoyer M, Haustermans K, Georg P, Burnet N, Kirkby K, Gregoire V, Calugaru V, Troost E, Hoebers F, Calvo F, Widder J, Eberle F, van Vulpen M, Maingon P, Skóra T, Weber D, Bergfeldt K, Kubes J, Langendijk J. PH-0328 Current practice for selection of adult patients for proton therapy across Europe. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07301-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
30
|
Anemoni L, Cadeo M, Mancin A, Mascayano I, Preda L, Tampellini S, Orlandi E. PO-1951 Comparison between the use of PET and MRI 3.0 T in meningiomas. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08402-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
31
|
Chiovatero I, Mantovani C, Vella A, Iorio G, Orlandi E, Cerrato M, Cavallin C, Badellino S, Gastino A, Cuffini E, Levis M, Ricardi U. PO-1032 Effects of SRS in patients affected with brain metastases from NSCLC: a single institution report. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07483-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
32
|
Orlandi E, Duclos M, Iacovelli N, Berthel E, Deneuve S, Cavallo A, Valdagni R, Rancati T, Pereira S. PO-0980 Predicting toxicity after Head-and-Neck cancer RT: synergist role of biological markers & dosimetry? Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07431-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, Halámková J, Mattheis S, Baujat B, Hardillo J, Smeele L, van Herpen C, Castro A, Machiels JP. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up †. Ann Oncol 2021; 32:452-465. [PMID: 33358989 DOI: 10.1016/j.annonc.2020.12.007] [Citation(s) in RCA: 132] [Impact Index Per Article: 44.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 12/10/2020] [Accepted: 12/12/2020] [Indexed: 12/24/2022] Open
Affiliation(s)
- P Bossi
- Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University of Brescia, ASST-Spedali Civili, Brescia, Italy
| | - A T Chan
- State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong, Special Administrative Region, People's Republic of China
| | - L Licitra
- Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, Milan, Italy
| | - A Trama
- Department of Research, Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - E Orlandi
- Radiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
| | - E P Hui
- State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong, Special Administrative Region, People's Republic of China
| | - J Halámková
- Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - S Mattheis
- Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Essen, Essen, Germany
| | - B Baujat
- Sorbonne University, APHP, Department of ENT - Head and Neck Surgery, Tenon Hospital, Paris, France
| | - J Hardillo
- Department of ENT - Head and Neck Surgery, Erasmus Medical Center Rotterdam, Rotterdam
| | - L Smeele
- Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - C van Herpen
- Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - A Castro
- Administration Board of Centro Hospitalar e Universitário do Algarve, Portugal
| | - J-P Machiels
- Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Institut de Recherche Clinique et Expérimentale (POLE MIRO), Université Catholique de Louvain, Brussels, Belgium
| |
Collapse
|
34
|
Elisei G, Pella A, Ricotti R, Via R, Fiore MR, Calvi G, Mastella E, Paganelli C, Tagaste B, Bello F, Fontana G, Meschini G, Buizza G, Valvo F, Orlandi E, Ciocca M, Baroni G. Development and validation of a new set-up simulator dedicated to ocular proton therapy at CNAO. Phys Med 2021; 82:228-239. [PMID: 33657472 DOI: 10.1016/j.ejmp.2021.01.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Revised: 11/27/2020] [Accepted: 01/14/2021] [Indexed: 10/22/2022] Open
Abstract
An Eye Tracking System (ETS) is used at CNAO for providing a stable and reproducible ocular proton therapy (OPT) set-up, featuring a fixation light (FL) and monitoring stereo-cameras embedded in a rigid case. The aim of this work is to propose an ETS set-up simulation algorithm, that automatically provides the FL positioning in space, according to patient-specific gaze direction and avoiding interferences with patient, beam and collimator. Two configurations are provided: one in the CT room for acquiring images required for treatment planning with the patient lying on a couch, and one related to the treatment room with the patient sitting in front of the beam. Algorithm validation was performed reproducing ETS simulation (CT) and treatment (room) set-up for 30 patients previously treated at CNAO. The positioning accuracy of the device was quantified through a set of 14 control points applied to the ETS case and localizable both in the CT volume and in room X-ray images. Differences between the position of ETS reference points estimated by the algorithm and those measured by imaging systems are reported. The corresponding gaze direction deviation is on average 0.2° polar and 0.3° azimuth for positioning in CT room and 0.1° polar and 0.4° azimuth in the treatment room. The simulation algorithm was embedded in a clinically usable software application, which we assessed as capable of ensuring ETS positioning with an average accuracy of 2 mm in CT room and 1.5 mm in treatment room, corresponding to gaze direction deviations consistently lower than 1°.
Collapse
Affiliation(s)
- G Elisei
- Centro Nazionale di Adroterapia Oncologica CNAO, Clinical Department-Bioengineering Unit, Pavia, Italy
| | - A Pella
- Centro Nazionale di Adroterapia Oncologica CNAO, Clinical Department-Bioengineering Unit, Pavia, Italy.
| | - R Ricotti
- Centro Nazionale di Adroterapia Oncologica CNAO, Clinical Department-Bioengineering Unit, Pavia, Italy
| | - R Via
- Center of Proton Therapy, Paul Scherrer Institut, 5232 Villigen, PSI, Switzerland
| | - M R Fiore
- Centro Nazionale di Adroterapia Oncologica CNAO, Clinical Department, Pavia, Italy
| | - G Calvi
- Centro Nazionale di Adroterapia Oncologica CNAO, Particle Accelerator Department, Pavia, Italy
| | - E Mastella
- Centro Nazionale di Adroterapia Oncologica CNAO, Clinical Department - Medical Physics Unit, Pavia, Italy
| | - C Paganelli
- Politecnico di Milano, Department of Electronics Information and Bioengineering, Milano, Italy
| | - B Tagaste
- Centro Nazionale di Adroterapia Oncologica CNAO, Clinical Department-Bioengineering Unit, Pavia, Italy
| | - F Bello
- Centro Nazionale di Adroterapia Oncologica CNAO, Clinical Department-Bioengineering Unit, Pavia, Italy
| | - G Fontana
- Centro Nazionale di Adroterapia Oncologica CNAO, Clinical Department-Bioengineering Unit, Pavia, Italy
| | - G Meschini
- Politecnico di Milano, Department of Electronics Information and Bioengineering, Milano, Italy
| | - G Buizza
- Politecnico di Milano, Department of Electronics Information and Bioengineering, Milano, Italy
| | - F Valvo
- Centro Nazionale di Adroterapia Oncologica CNAO, Clinical Department, Pavia, Italy
| | - E Orlandi
- Centro Nazionale di Adroterapia Oncologica CNAO, Clinical Department, Pavia, Italy
| | - M Ciocca
- Centro Nazionale di Adroterapia Oncologica CNAO, Clinical Department - Medical Physics Unit, Pavia, Italy
| | - G Baroni
- Centro Nazionale di Adroterapia Oncologica CNAO, Clinical Department-Bioengineering Unit, Pavia, Italy; Politecnico di Milano, Department of Electronics Information and Bioengineering, Milano, Italy
| |
Collapse
|
35
|
Fochi S, Orlandi E, Ceccuzzi L, Rodolfo M, Vergani E, Turco A, Romanelli MG, Gomez-Lira M. Identification of suitable mRNAs and microRNAs as reference genes for expression analyses in skin cells under sex hormone exposure. Gene 2020; 769:145336. [PMID: 33301797 DOI: 10.1016/j.gene.2020.145336] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Revised: 10/02/2020] [Accepted: 11/27/2020] [Indexed: 12/27/2022]
Abstract
Quantitative RT-PCR is the most accurate technique for the study of gene expression profiles, however, to ensure the accuracy of qPCR results, suitable reference genes are necessary for data normalization. Hormones influence the development and function of skin cells, regulating the expression of genes and miRNAs. Nevertheless, the stability of reference genes after sex hormone treatment has not been thoroughly investigated. In this study, we evaluated the expression of a set of candidate mRNAs and microRNsA (miRNA) as reference genes in keratinocytes (HaCaT cells), primary human fibroblasts and a melanoma cell line (LM-36 cells) under testosterone or 17β-estradiol treatment. Two algorithms, namely geNorm, Best-Keeper, and the comparative ΔCt method were used to evaluate the expression stability of the candidate reference genes. The comprehensive ranking showed that TBP and miR-191-5p are the most stable expressed genes across all cultured cells under hormone treatment. Furthermore, we observed that GAPDH, HPRT1 and U6 snRNA expression may be altered by hormone exposure, thus, these genes are not recommended as reference genes. In conclusion, the present study provides, to the best of our knowledge, the first evaluation of expressed mRNA(s) and miRNA(s) as reference genes in three different types of skin cells under the stimulation of sex hormones.
Collapse
Affiliation(s)
- S Fochi
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Italy.
| | - E Orlandi
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Italy.
| | - L Ceccuzzi
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Italy.
| | - M Rodolfo
- Melanoma and Sarcoma Surgery Unit and Unit of Immunotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| | - E Vergani
- Melanoma and Sarcoma Surgery Unit and Unit of Immunotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| | - A Turco
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Italy.
| | - M G Romanelli
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Italy.
| | - M Gomez-Lira
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Italy.
| |
Collapse
|
36
|
Levis M, De Luca V, Bartoncini S, Orlandi E, Iorio G, Parise R, Palladino C, Cavallin C, Botto B, Giglioli F, Fiandra C, Ricardi U. OC-0459: Clinical outcomes in Hodgkin Lymphoma patients treated with IMRT-VMAT according to ISRT principles. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00481-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
37
|
Chiovatero I, Mantovani C, Iorio G, Cavallin C, Vella A, Orlandi E, Cerrato M, Badellino S, Caivano D, Levis M, De Luca V, Ricardi U. PO-0899: Risk of brain Radionecrosis after radiosurgery in oligometastatic patients. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00916-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
38
|
Vischioni B, Mirandola A, Bonora M, Ronchi S, Mastella E, Orlandi E, Iacovelli N, Cavallo A, Licitra L, Fallai C, Ciocca M, Pignoli E, Magrini S, Antognoni P, Valvo F. PO-1798: Quality of radiotherapy treatment plans for locally advanced sinonasal tumors in a phase II trial. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01816-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
39
|
Cavallo A, Rancati T, Iacovelli N, Facchinetti N, Alfieri S, Cavalieri S, Giandini T, Cicchetti A, Ingargiola R, Romanello D, Di Biaso S, Sabetti M, Fallai C, Licitra L, Locati L, Pignoli E, Valdagni R, Orlandi E. PD-0545: Validation of a predictive model for salivary dysfunction during chemo-IMRT for head-neck cancer. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00567-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
40
|
Orlandi E, Calareso G, Tenconi C, Rancati T, Iacovelli N, Cavallo A, Facchinetti N, Ingargiola R, Ivaldi E, Romanello D, Corino V, Valdagni R, Cavalieri S, Alfieri S, Licitra L, Pignoli E, Mainardi L, Fallai C, Bologna M. PO-1577: Baseline MRI-radiomics can predict overall survival in non endemic nasopharyngeal cancer patients. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01595-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
De Luca V, Bartoncini S, Iorio G, Parise R, Orlandi E, Cavallin C, Palladino C, Levis M, Ricardi U. PO-0920: Low dose radiation therapy (2 Gy x 2) in the treatment of Marginal Zone Lymphomas. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00937-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
42
|
Orlandi E, De Luca V, Gallio E, Bartoncini S, Iorio G, Parise R, Cavallin C, Palladino C, Fiandra C, Levis M, Ricardi U. OC-0201: Hodgkin Lymphoma patients treated with IMRT: from dosimetric analysis to cardiovascular disease risk. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00225-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
43
|
Jereczek-Fossa BA, Palazzi MF, Soatti CP, Cazzaniga LF, Ivaldi GB, Pepa M, Amadori M, Antognoni P, Arcangeli S, Buffoli A, Beltramo G, Berlinghieri S, Bignardi M, Bracelli S, Bruschieri L, Castiglioni S, Catalano G, Di Muzio N, Fallai C, Fariselli L, Filippi AR, Gramaglia A, Italia C, Lombardi F, Magrini SM, Nava S, Orlandi E, Pasinetti N, Sbicego EL, Scandolaro L, Scorsetti M, Stiglich F, Tonoli S, Tortini R, Valdagni R, Vavassori V, Marvaso G. COVID-19 Outbreak and Cancer Radiotherapy Disruption in Lombardy, Northern Italy. Clin Oncol (R Coll Radiol) 2020; 32:e160-e161. [PMID: 32354669 PMCID: PMC7177150 DOI: 10.1016/j.clon.2020.04.007] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2020] [Accepted: 04/17/2020] [Indexed: 11/18/2022]
Affiliation(s)
- B A Jereczek-Fossa
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy
| | - M F Palazzi
- Radiotherapy Unit, ASST Ospedale Niguarda, Milano, Italy
| | - C P Soatti
- Radiation Oncology Center, Ospedale Manzoni, Lecco, Italy
| | - L F Cazzaniga
- Radiation Oncology Center, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - G B Ivaldi
- Radiation Oncology Center, Istituti Clinici Scientifici Maugeri, IRCCS, Pavia, Italy
| | - M Pepa
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milano, Italy
| | - M Amadori
- Radiation Oncology Center, Ospedale C. Poma, Mantova, Italy
| | - P Antognoni
- Radiation Oncology Center, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese, Italy
| | - S Arcangeli
- Department of Radiation Oncology, Policlinico S. Gerardo and University of Milan "Bicocca", Milano, Italy
| | - A Buffoli
- Radiation Oncology Center, Istituto Clinico S. Anna, Brescia, Italy
| | - G Beltramo
- Radiation Oncology Center, Centro Diagnostico Italiano (CDI), Milano, Italy
| | - S Berlinghieri
- Unit of Radiotherapy, Ospedale di Esine - ASL Vallecamonica-Sebino, Esine, Italy
| | - M Bignardi
- Radiation Oncology Center, Fondazione Poliambulanza, Brescia, Italy
| | - S Bracelli
- Radiation Oncology Center, Ospedale, Busto Arsizio, Italy
| | - L Bruschieri
- Division of Radiation Oncology, Ospedale di Treviglio, Caravaggio di Treviglio, Italy
| | - S Castiglioni
- Radiation Oncology Center, S. Pio X-Humanitas, Milano, Italy
| | - G Catalano
- Radiation Oncology Center, IRCCS Ospedale Multimedica, Sesto San Giovanni/Castellanza, Italy
| | - N Di Muzio
- Radiation Oncology Center, IRCCS Ospedale S. Raffaele and University Vita Salute, Milano, Italy
| | - C Fallai
- Division of Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - L Fariselli
- Radiotherapy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
| | - A R Filippi
- Radiation Oncology Department, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
| | - A Gramaglia
- Radiation Oncology Center, Policlinico, Monza, Italy
| | - C Italia
- Radiation Oncology Center, Istituti Ospedalieri Bergamaschi, Ponte S. Pietro-Zingonia, Italy
| | - F Lombardi
- Radiotherapy Unit, IRCCS Policlinico San Donato, San Donato Milanese, Italy
| | - S M Magrini
- Radiation Oncology Center, Brescia University Radiation Oncology Department, O. Alberti Radium Institute, Spedali Civili Hospital, Brescia, Italy
| | - S Nava
- Radiation Oncology Center, Istituti Clinici di Pavia e Vigevano, Vigevano, Italy
| | - E Orlandi
- Radiation Oncology Center, National Center of Oncological Hadrontherapy, CNAO, Pavia, Italy
| | - N Pasinetti
- Radiation Oncology Department, Esine and University of Brescia, Esine, Italy
| | - E L Sbicego
- Radiation Oncology Center, Istituto Clinico Sant'Ambrogio, Milano, Italy
| | - L Scandolaro
- Radiation Oncology Center, Ospedale Sant'Anna, ASST Lariana, Como, Italy
| | - M Scorsetti
- Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Hospital - IRCCS, Rozzano, MI, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy
| | - F Stiglich
- Radiation Oncology Center, Ospedale, Sondrio, Italy
| | - S Tonoli
- Radiation Oncology Center, Ospedale, Cremona, Italy
| | - R Tortini
- Ospedale di Casalpusterlengo, Azienda Ospedaliera della Provincia di Lodi, Casalpusterlengo, Italy
| | - R Valdagni
- Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy; Division of Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - V Vavassori
- Unit of Radiotherapy, Cliniche Gavezzeni SPA, Bergamo, Italy
| | - G Marvaso
- Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy
| |
Collapse
|
44
|
Bossi P, Grisanti S, Mohamad I, Linares Galiana I, Ozyar E, Franco P, Vecchio S, Livi L, Cirauqui Cirauqui B, El-Sherify M, Ursino S, Argiris A, Pan J, Wittekindt C, D’angelo E, Buglione M, Airoldi M, Mesia Nin R, Licitra L, Orlandi E. Survival and prognostic factors of nasopharyngeal cancer patients in non-endemic countries: A large multicentric database analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz252.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Deneuve S, Rancati T, Bastogne T, Duclos M, Bois P, Bachman P, Roux P, Girodet D, Poupart M, Zrounba P, Mallet C, Claude L, Ferella L, Orlandi E, Pereira S. Approach Combining Dosimetry and Biology to Predict Severe Toxicity of Radiotherapy for Head and Neck Squamous Cell Carcinomas. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Rancati T, Bedini N, De Cecco L, Avuzzi B, Morlino S, Noris Chiorda B, Dispinzieri M, Villa S, Di Florio T, Badenchini F, Palorini F, Giandini T, Cicchetti A, Mancinelli E, Serafini M, De Vecchi A, Orlandi E, Valdagni R. OC-0616 Introducing information on gut microbiota into toxicity modeling: preliminary results from a trial. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31036-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
47
|
Ferella L, Vittorini F, Varrassi E, Franzese P, Di Staso M, Marampon F, Sorce C, Chalaszczyk A, Grimaldi G, Di Cesare E, Orlandi E, Tombolini V, Masciocchi C, Gravina G. EP-1187 Different carotid contouring results in dosimetric variability and significant anatomical missing. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31607-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
48
|
Cavallo A, Iacovelli N, Rancati T, Facchinetti N, Di Florio T, Doldi V, Campi E, Zaffaroni N, Giandini T, Ferella L, Romanello D, Delle Curti C, Bossi P, Pignoli E, Fallai C, Valdagni R, Orlandi E. EP-1190 Preliminary evaluation of salivary cytokines in patients treated with IMRT for head and neck cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31610-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Ferella L, Vittorini F, Varrassi E, Franzese P, Di Staso M, Marampon F, Sorce C, Chalaszczyk A, Grimaldi G, Di Cesare E, Orlandi E, Tombolini V, Masciocchi C, Gravina G. EP-1186 The new target delineation impact on carotid and bulb sparing for T1 glottic cancer: VMAT vs 3DCRT. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31606-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
50
|
Iacovelli N, Cavallo A, Cicchetti A, Ferella L, Facchinetti N, Giandini T, Meroni S, Romanello D, Bossi P, Licitra L, Pignoli E, Fallai C, Orlandi E. PO-0729 Prognostic factors analysis in a cohort of Nasopharyngeal cancer patients with 5-year follow-up. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31149-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|